- Corporate Officers - G
- Gillis Steven
Insider Trading History of Gillis Steven
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Gillis Steven since 2017.
This trader's CIK number is 1229592.
At the time of last reporting, Gillis Steven was the 10% Owner of Prime Medicine, Inc.. (stock ticker symbol PRME).
Also see all insider trading activities at Prime Medicine, Inc..
Note that in the past
GILLIS STEVEN also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Vbi Vaccines Inc/bc (VBIV) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | VBIV | 609,090 | $1,004,998 | 0 | $0 | 0 | $0 |
| 2019 | VBIV | 0 | $0 | 0 | $0 | 18,750 | $0 |
| 2018 | VBIV | 0 | $0 | 0 | $0 | 18,750 | $0 |
| 2017 | VBIV | 300,000 | $915,000 | 0 | $0 | 25,127 | $15,942 |
Yearly summary of insider trading at Prime Medicine, Inc. (PRME) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | PRME | 3,030,300 | $9,999,990 | 0 | $0 | 0 | $0 |
| 2024 | PRME | 3,200,000 | $20,000,000 | 0 | $0 | 0 | $0 |
| 2022 | PRME | 800,000 | $13,600,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Codiak Biosciences, Inc. (CDAK) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | CDAK | 0 | $0 | 0 | $0 | 8,750 | $0 |
| 2022 | CDAK | 5,000,000 | $0 | 0 | $0 | 0 | $0 |
| 2020 | CDAK | 235,000 | $3,525,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Sana Biotechnology, Inc. (SANA) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | SANA | 1,818,181 | $9,999,995 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Boundless Bio, Inc. (BOLD) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | BOLD | 200,000 | $3,200,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Da32 Life Science Tech Acquisition Corp. (DALS) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | DALS | 1,600,000 | $16,000,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Sienna Biopharmaceuticals, Inc. (SNNA) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | SNNA | 6,497,400 | $16,243,500 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Vbi Vaccines Inc. (VBIV) by Gillis Steven
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | VBIV | 10,000,000 | $5,000,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 8 companies by Gillis Steven:
1. Vbi Vaccines Inc/bc (VBIV)
2. Prime Medicine, Inc. (PRME)
3. Codiak Biosciences, Inc. (CDAK)
4. Sana Biotechnology, Inc. (SANA)
5. Boundless Bio, Inc. (BOLD)
6. Da32 Life Science Tech Acquisition Corp. (DALS)
7. Sienna Biopharmaceuticals, Inc. (SNNA)
8. Vbi Vaccines Inc. (VBIV)
Table 1. Insider trading of Vbi Vaccines Inc/bc (VBIV) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-07-10 | VBIV | Buy | 609,090 | 1.65 | 1,004,998 |
| 2019-06-14 | VBIV | Option Ex | 18,750 | .00 | 0 |
| 2018-06-14 | VBIV | Option Ex | 18,750 | .00 | 0 |
| 2017-10-30 | VBIV | Buy | 300,000 | 3.05 | 915,000 |
| 2017-06-14 | VBIV | Option Ex | 18,750 | .00 | 0 |
| 2017-01-17 | VBIV | Option Ex | 6,377 | 2.50 | 15,942 |
Table 2. Insider trading of Prime Medicine, Inc. (PRME) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-08-01 | PRME | Buy | 3,030,300 | 3.30 | 9,999,990 |
| 2024-02-15 | PRME | Buy | 3,200,000 | 6.25 | 20,000,000 |
| 2022-10-24 | PRME | Buy | 800,000 | 17.00 | 13,600,000 |
Table 3. Insider trading of Codiak Biosciences, Inc. (CDAK) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-02-16 | CDAK | Option Ex | 8,750 | .00 | 0 |
| 2022-09-13 | CDAK | Buy | 5,000,000 | .00 | 0 |
| 2020-10-16 | CDAK | Buy | 235,000 | 15.00 | 3,525,000 |
Table 4. Insider trading of Sana Biotechnology, Inc. (SANA) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-02-08 | SANA | Buy | 1,818,181 | 5.50 | 9,999,995 |
Table 5. Insider trading of Boundless Bio, Inc. (BOLD) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-04-02 | BOLD | Buy | 200,000 | 16.00 | 3,200,000 |
Table 6. Insider trading of Da32 Life Science Tech Acquisition Corp. (DALS) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-07-30 | DALS | Buy | 1,600,000 | 10.00 | 16,000,000 |
Table 7. Insider trading of Sienna Biopharmaceuticals, Inc. (SNNA) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-02-22 | SNNA | Buy | 2,165,800 | 2.50 | 5,414,500 |
| 2019-02-22 | SNNA | Buy | 2,165,800 | 2.50 | 5,414,500 |
| 2019-02-22 | SNNA | Buy | 2,165,800 | 2.50 | 5,414,500 |
Table 8. Insider trading of Vbi Vaccines Inc. (VBIV) by Gillis Steven
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-09-19 | VBIV | Buy | 10,000,000 | .50 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Gillis Steven
(10% Owner of Prime Medicine, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.